Purpose Natural products represent a rich reservoir of potential small molecule inhibitors exhibiting antiproliferative and tumoricidal properties. An example is the isoquinoline alkaloid berberine, which is found in plants such as goldenseal (Hydrastis canadensis). Studies have shown that berberine is able to trigger apoptosis in diVerent malignant cell lines, and can also lead to cell cycle arrest at sub-apoptotic doses. A particularly interesting feature of berberine is the fact that it is a Xuorescent molecule, and its uptake and distribution in cells can be studied by Xow cytometry and epiXuorescence microscopy. To test the relationships between berberine uptake, distribution and cellular eVect in melanoma cells, K1735-M2 mouse and WM793 human melanoma cells were treated with diVerent concentrations of berberine, and alterations in cell cycle progression, DNA synthesis, cell proliferation, and cell death measured. Methods Cell proliferation was measured by sulforhodamine B assays, cell death by Xow cytometry, berberine uptake and distribution by laser scanning confocal microscopy and Xow cytometry, cell cycle progression by Xow cytometry, and DNA synthesis, M-phase, and mitochondrial eVects by immunolabeling and epiXuorescence microscopy methods. Results In these melanoma cell lines, berberine at low doses (12.5-50 M) is concentrated in mitochondria and promotes G1 arrest. In contrast, higher doses (over 50 M) result in cytoplasmic and nuclear berberine accumulation, and G2 arrest. DNA synthesis is not markedly aVected by low doses of berberine, but 100 M is strongly inhibitory. Even at 100 M, berberine inhibits cell growth with relatively little induction of apoptosis. Conclusion Berberine displays multiphasic eVects in these malignant cell lines, which are correlated with the concentration and intracellular distribution of this alkaloid. These results help explain some of the conXicting information in the literature regarding the eVects of berberine, and suggest that its use in clinical development may be more as a cytostatic agent than a cytotoxic compound.
Introduction
Berberine is an isoquinoline alkaloid present in a number of plant species that have long histories of use in ayurvedic, unani, Chinese, and native American traditional medicine practices [1, 2] . Berberine has been associated with a wide variety of biological eVects, including anti-microbial, antiinXammatory, anti-diarrheal, anti-nociceptive and antipyretic activities. It has been reported to lower cholesterol, control blood sugar levels, and function as an anti-oxidant.such as psoriasis and cancer (reviewed in [3, 4] ). A popular source of berberine and other isoquinoline alkaloids is the plant Hydrastis canadensis, or goldenseal. Goldenseal has been reported to be one of the Wve top-selling herbal products in the US (http://www.nlm.nih.gov/medlineplus/druginfo/natural/patient-goldenseal.html), and, along with ginseng, is one of the most over-harvested plants in the US [5] . Consequently, there are a number of compelling reasons to study the actions, including possible harmful side eVects, of berberine and related alkaloids.
A growing number of studies are focusing on the ability of berberine to function as an anti-cancer drug through its ability to induce apoptosis in a number of diVerent malignant cell lines. Berberine has been reported to induce apoptosis through a mitochondrial pathway that includes upregulation of p53, alterations in Bcl-2/Bax ratios, a decrease in mitochondrial membrane potential, release of cytochrome c, and activation of caspases [2, [6] [7] [8] [9] [10] [11] [12] . This is of particular interest in light of studies demonstrating a mitochondrial localization of berberine, raising the possibility that apoptosis results from mitochondrial damage induced by berberine. Alternatively, berberine also binds DNA and RNA (reviewed in Ref. [3] ), and apoptosis may be triggered downstream of a DNA damage response. To investigate these questions in more detail, we treated K1735-M2 melanoma cells with diVerent concentrations of berberine for various lengths of time and correlated berberine localization patterns with eVects on cell proliferation, cell cycle progression, and cell death. The results of these studies indicate that the primary eVect of berberine in these cells is cytostatic rather than cytotoxic, and that the inhibition of cell proliferation reXects a multiphase response to berberine that is associated with concentration-dependent diVerences in localization patterns.
Materials and methods
Cell culture K1735-M2 mouse melanoma cells (the kind gift of Dr Lillian Repesh, Department of Anatomy, Microbiology, and Pathology, University of Minnesota School of Medicine, Duluth, MN, USA) and WM793 human vertical growth phase melanoma cells (the kind gift of Dr Meenhard Herlyn, Wistar Institute, Philadelphia, PA, USA) were grown in Dulbecco's modiWed Eagle's medium (GIBCO, Grand Island, NY, USA) and 10% Fetal Clone III (FC3; HyClone, Logan, UT, USA) in a 5% CO 2 atmosphere at 37°C. Cells were passaged by trypsinization using standard methods; all experiments were seeded from cultures in log-phase growth.
Cell proliferation measurements Sulforhodamine B assays [13] were conducted to measure the eVects of berberine on the proliferation of M2 cells, essentially as described by Holy et al. [14] . Cells were seeded at a concentration of 1 £ 10 4 cells/ml in 24-well plates, and allowed to recover for 1 day prior to drug addition. Stock solutions of 25 mM berberine chloride (Sigma Chemical Co., St Louis, MO, USA) were prepared in dimethylsulfoxide (DMSO) and stored frozen; for experiments, aliquots were thawed and diluted into culture medium at the desired concentration. Vehicle controls received an equivalent amount of DMSO only. After sulforhodamine labeling, absorbance was measured in a spectrophotometer at 540 nm; the amount of dye released is proportional to the number of cells present in the dish, and is a reliable indicator of cell proliferation.
Cell death assays
After berberine or DMSO (vehicle only control) treatment, culture media was collected from the samples and saved. Cells were trypsinized, and added back to the saved media in order to collect both adherent cells as well as non-adherent (dead and dying) cells Xoating in the media. Cells were collected by centrifugation and resuspended in PBS containing 5% fetal bovine serum. Components of the live/dead kit (calcein-AM and ethidium homodimer; Molecular Probes, Eugene, OR, USA) were added according to manufacturer's instructions, and cells incubated at 37°C for 15 min. The FL1 (calcein, green) signal and FL3 (ethidium, red) signal were measured with a Becton-Dickenson FACScalibur Xow cytometer. The red-Xuorescing cells were discriminated from the greenXuorescing cells and counted using the cytometer Cell Quest software package.
Measurement of berberine uptake
For time-course studies, berberine was added to 100 M to dishes of M2 cells 360, 300, 240, 180, 120, 60 and 30 min prior to harvesting by trypsinization. Cells were resuspended in PBS-5% FC3, and immediately measured with a Becton-Dickenson Xow cytometer, using the FL1 Wlter set. For dose-response studies, a range of berberine concentrations (12.5-150 M) was added to dishes of M2 cells 2.5 h prior to trypsinization, resuspension in PBS-5% FC3, and measurement with the Xow cytometer. For all samples, approximately 15 min had elapsed between removal of berberine-containing culture media and the measurement of berberine Xuorescence intensity.
Confocal microscopy of berberine localization Cells were seeded into 35 mm glass-bottom petri dishes (MatTek Inc., Amherst, MA, USA) at a density of 1 £ 10 4 / ml, and allowed to recover for 24 h prior to use. A range of concentrations of berberine was added to the dishes; after 2 h, the dishes were removed from the incubator and placed on the stage of a Nikon C1 laser-scanning confocal microscope. Laser excitation and PMT gain were set at values to best visualize the range of Xuorescence emitted by cultures treated with 12.5-150 M berberine. Berberine Xuorescence was imaged using a Spectra Physics Krypton-Argon Model 163C polarized laser (40 mW at 488 nm) and a 545 nm dichroic long pass, with a 605/75 band pass for the red channel (PMT 2). For documentation purposes, this red signal was converted to green using image-processing methods, in order to reveal better morphological detail. All pictures were obtained and processed using identical settings in order to directly compare diVerences in Xuorescence intensity or localization patterns.
Cell cycle analysis
Cells in log-phase growth were treated with diVerent concentrations of berberine for various lengths of time, trypsinized, resuspended, and Wxed with cold (¡10°C) 70% ethanol. Cells were subsequently washed in PBST and resuspended in 0.5 ml PBST containing 20 g/ml RNase, and incubated at 37°C for 45 min. Propidium iodide was added to 20 g/ml, and cells stained for 30 min at 37°C. DNA quantity was measured using a Becton-Dickenson FACScalibur Xow cytometer (BD Biosciences, San Jose, CA, USA). The percentage of cells in G1, S and G2/M in each sample was determined using ModWt LT software (Verity Software House, Topsham, ME, USA). In some experiments, FCCP (carbonyl cyanide 4-(triXuoromethoxy)phenylhydrazone) (Sigma Chem. Co.) was added to 10 M, with or without berberine. Control cultures received an equivalent amount of vehicle (DMSO) only, which never exceeded 0.1% v/v.
M-phase quantitation
To quantitate the percentage of cells in M-phase, M2 cells were seeded onto glass coverslips and grown in the presence of 100 M berberine (or an equivalent amount of DMSO only) for 24 h. Cells were then Wxed in freezer-temperature absolute methanol, and subsequently immunolabeled using a monoclonal antibody to -tubulin (E7; Developmental Studies Hybridoma Bank, Iowa City, IA, USA), followed by a goat-anti-mouse-Texas Red secondary antibody (Jackson Immunoresearch, Malvern, PA, USA). Chromatin was counterstained by adding Hoechst 33258 (Sigma Chem. Co.) to the secondary antibody at 5 g/ml. Cells were examined by epiXuorescence microscopy to identify M-phase cells, which were easily identiWable as rounded cells containing mitotic spindles and condensed chromatin. For quantitation, random Welds of view were selected, and both the total number of cells and the number of M-phase cells counted. At least Wve Welds of view were counted for each sample, with a total of 500 cells counted per sample.
BrdU labeling
At various time points after the addition of berberine (or DMSO vehicle only), cells were pulse-labeled with 10 M bromodeoxyuridine (BrdU; Sigma Chem. Co.) for 30 min and then Wxed in cold (¡10°C) absolute methanol. For BrdU labeling, cells were rehydrated with PBST and treated with 2 N HCl for 20 min at room temperature. Cells were then washed Wve times with PBST, and incubated in PBST containing 0.5% non-fat powdered milk for 30 min at 37°C. Cells were immunolabeled and counterstained with Hoechst as described above, using a labeled anti-BrdU antibody (G3G4, Developmental Studies Hybridoma Bank).
Evaluation of mitochondrial eVects of berberine K1735-M2 and WM793 cells were seeded in 35 mm glassbottom petri dishes as described above, and subsequently treated with either 25 M berberine or vehicle only (0.1% DMSO) for 6 h. Hoechst 33342 (Sigma) and tetramethylrhodamine methyl ester (TMRM; Invitrogen Corp., Carlsbad, CA, USA) were added to 2 g/ml and 100 nM, respectively, and the dishes incubated for 30 min prior to examination by epiXuorescence microscopy. All TMRM images from control and berberine-treated samples were taken at the same exposure times and processed identically in order to compare Xuorescence intensities.
Results

EVect of berberine on cell proliferation
The eVects of a range of concentrations of berberine (5-100 M) on cell proliferation was measured for up to 6 days ( Fig. 1) . Sulforhodamine B assays demonstrate that a single application of berberine leads to a signiWcant and dose-dependent inhibition of M2 proliferation over a number of days at concentrations as low as 5 M (Fig. 1a) . About 50 M berberine was strongly cytostatic, and 100 M completely inhibited cell proliferation (Fig. 1b) . ). These results demonstrate that berberine has signiWcant cytostatic eVects, but is cytotoxic to these cells only at very high concentrations.
Uptake and compartmentalization of berberine
Because berberine is a Xuorescent compound that can be detected by both epiXuorescence microscopy and Xow cytometry, we measured the uptake and distribution of berberine in living M2 cells using these methods. Measurements of total cellular Xuorescence by Xow cytometry showed that 100 M berberine took between 1 and 2 h to accumulate to a maximum level within cells, and this level was quite stable for at least 6 h (Fig. 3a) . The half-maximal value was achieved within 30 min, which correlates well with the appearance of mitochondrial berberine Xuorescence by microscopy (see below). Comparison of the Xuorescence levels of diVerent concentrations of berberine at a 2.5 h time point demonstrates that an essentially linear uptake of berberine occurs between 12.5 and 150 M (the extent of the range tested; Fig. 3b ). The eVect of FCCP on the uptake of diVerent concentrations of berberine was also examined. Addition of FCCP had little eVect on the uptake of 50 M or less berberine after 2 h, but signiWcantly increased the berberine signal in cultures treated with 100 M or more (Fig. 3c) .
Confocal microscopy demonstrates that the diVerent concentrations of berberine exhibit diVerent intracellular distribution patterns of Xuorescent signals. Low concentrations of berberine (e.g., 12.5 M or less) are not readily detectable within M2 cells at the gain settings used to avoid grossly oversaturating the signal emitted by higher concentrations of berberine. On the other hand, strong mitochondrial Xuorescence is apparent in cells treated with 25 or (Fig. 4) . This Xuorescence becomes noticeable by microscopy after about 20-30 min of incubation, which correlates well with the increase in signal detected by Xow cytometry (Fig. 3a) . The entire cytoplasm, as well as nuclei and nucleoli, becomes Xuorescent in cells incubated in 100 M or more berberine (Fig. 4) .
EVects of berberine on the cell cycle DiVerent berberine concentrations and exposure times result in a number of distinct perturbations in cell cycle progression (Figs. 5, 6 ). Twenty-Wve micromole berberine leads to an increase in the percentage of cells in G1, which becomes more pronounced at days 2 and 3 after addition. In contrast, 100 M berberine does not lead to a similar G1 increase, but rather results in a marked increase in the percentage of cells in G2/M. Fifty micromole berberine appears to be intermediate between these patterns in its eVects. All concentrations of berberine tested (25, 50 and 100 M) reduce the percentage of cells in S-phase, with a noticeable time-dependence eVect for 25 M. Because of the possibility that berberine may be interfering with normal mitochondrial function (due to its mitochondrial localization), the pattern of cell cycle disruption of a known mitochondrial poison, FCCP, was compared with that of berberine. Interestingly, 10 M FCCP by itself bore many similarities to the eVects of 12.5 and 25 M berberine (Fig. 7) . Like these concentrations of berberine, FCCP caused an increase in G1, suppressed S-phase, and had little eVect on the percentage of cells in G2/M. Co-treatment with 25 M berberine and 10 M FCCP dampened the increase in G1, and increased the percentage of cells in G2/ M. Therefore, the addition of FCCP to low concentrations of berberine resulted in cell cycle proWles that more resembled those of cells exposed to high concentrations of berberine alone.
To distinguish whether the increase in the number of cells in G2/M following treatment with 100 M berberine was due to a block in G2 or M, the number of M-phase cells (cells containing mitotic spindles and condensed chromatin) were counted after a 24 h exposure. The percentage of cells in M-phase was signiWcantly decreased after treatment, indicating that high concentrations of berberine induce a G2 block prior to entry into M-phase (Fig. 8) .
To investigate the time-course of the reduction of cells in S-phase by berberine, M2 cells were treated with berberine, and then pulse-labeled with BrdU. Two hours after berberine addition, BrdU labeling was still observed in control, 25 and 50 M berberine cultures, but the intensity of labeling appeared to be somewhat diminished in the 25, and especially 50 M cultures (Fig. 9) . In contrast, DNA synthesis was signiWcantly reduced in cultures treated with 100 M berberine, although some labeling was still present in these cells. 24 and 48 h after addition of berberine, BrdU labeling was still present in cultures treated with either 25 or 50 M berberine, but the percentage of cells exhibiting a BrdU signal appears to be diminished. At 96 h of treatment, some cells are still labeled in the 25 M berberine cultures, but BrdU uptake is essentially totally suppressed in the 50 M cultures. DNA synthesis in the 100 M cultures remained completely inhibited at all of these time points (Fig. 9) .
To determine whether the mitochondrial accumulation of lower concentrations of berberine caused perturbations in mitochondrial structure or function, K1735-M2 and WM793 melanoma cells were incubated in 25 M berberine for 6 h, and then labeled with tetramethylrhodamine methyl ester (TMRM), which is a polarization-dependent mitochondrial probe. Berberine treatment led to mitochondrial fragmentation in both of these melanoma cell lines (Fig. 10) . In addition, a reduction in mitochondrial TMRM Xuorescence intensity was noticeable, indicating that the mitochondrial membrane potential is diminished in the presence of berberine.
Discussion
Berberine is a Xuorescent compound, with absorbance peaks of 230, 267, 344 and 420 nm, and peak emission at 550 nm [3] . Although it has been utilized as a Xuorescent stain for mast cells [15, 16] , sperm and oocytes [17] , DNA and RNA [18] [19] [20] [21] , and mitochondria [22] , the kinetics of its uptake and distribution in living cells has not been extensively characterized. In this study, 25 and 50 M berberine strongly labeled mitochondria, with little detectable cytoplasmic or nuclear Xuorescence. However, both cytoplasm and nuclei became noticeably Xuorescent at higher concentrations of berberine (100 and 150 M). Previous studies demonstrated that berberine displays a striking increase in Xuorescence in the hydrophobic regions of polarized mitochondrial membranes, apparently due to an increase in quantum yield [23] . Although more berberine binds to energized mitochondria than non-energized mitochondria, this diVerence has been reported to be relatively minor [23] . Similarly, a dramatic increase in Xuorescence quantum yield also occurs upon DNA binding [19] . This behavior complicates the quantitative assessment of berberine localization within cells by Xuorescence methods. However, the overall berberine signal in nuclei, which, like mitochondria, would also be expected to display increases in Xuorescence quantum yield as berberine binds DNA, is very low in M2 cells treated with 25 and 50 M berberine. Instead, both nucleus and cytoplasm become steadily more Xuorescent as the concentration of berberine added to the cultures increases above 50 M. Although detailed washout experiments have not been conducted, the cytoplasm and nucleus appear to have aYnity for berberine, as the Xow cytometry data was obtained from cells that had been washed out of berberine (resuspended in PBS) for approximately 15 min. This conclusion is supported by previous studies reporting staining of nuclei and cytoplasm by berberine [20, 24, 25] . We interpret these results as indicating that most berberine preferentially accumulates in mitochondria at lower concentrations (<50 M), but these binding sites become saturated at higher concentrations (>50 M), and berberine subsequently accumulates in the cytoplasm and nucleus. If this is the case, then two sets of eVects could be expected to occur in berberine-treated cells: cells exposed to lower concentrations of berberine would be predicted to display primarily mitochondrial eVects, whereas cells exposed to higher concentrations of berberine could additionally exhibit a host of other alterations, including eVects resulting from perturbations of DNA organization and function.
Flow cytometry data indicates that total cellular accumulation of berberine did not appear to be saturated at the highest concentration (150 M) used in this study. On the other hand, time-course studies using 100 M berberine indicate that uptake reached a maximum by about 2 h, with about 50% entering cells within 30 min. Addition of 10 M FCCP signiWcantly enhanced the accumulation of 100 and 150 M berberine in M2 cells, raising the possibility that berberine is a substrate for drug eZux pumps, and that reduction of ATP levels by FCCP interferes with the export of higher concentrations of berberine. Berberine has been reported to inhibit P-gp activity in a number of transformed cell lines [26] , to mildly activate P-gp ATPase activity in brain [27] , and to up-regulate the expression of P-gp in oral, gastric, and colon cancer cells [28] . Inhibitors of MDR1 and MRP1, as well as reduction of ATP levels with sodium azide increased the cellular accumulation in human KB3-1 cells [29] .
Of course, for clinical relevance, uptake and metabolism of berberine in an in vivo situation must take into account route of delivery and pharmacokinetic considerations. Berberine has been shown to be rapidly absorbed by the small intestine in rats [30] , and less than 5% is eliminated from urine and bile after a bolus i.v. injection [31] . Relatively more metabolites than berberine were recovered from urine of human volunteers after oral ingestion of berberine [32] , suggesting that berberine metabolites may play important roles in vivo. Berberine is metabolized by the liver to berberrubine, thalifendine, demethyleneberberine, and jattrorhizine; interestingly, berberrubine and thalifendine inhibit topoisomerases II and I, respectively, and berberrubine has been shown to possess antitumor properties [33] [34] [35] . Based on in vitro Wndings that 1, 5 and 10 g/ml berberine were cytotoxic to B16 mouse melanoma cells, daily i.p. injections of 1, 5 and 10 mg/kg berberine were carried out in an in vivo melanoma transplant model; tumor weights were signiWcantly reduced in the 5 and 10 mg/kg animals [36] . These Wndings indicate that the lower concentrations of berberine used in this study are within the range of clinical relevance.
Subjectively, the strong mitochondrial berberine signal suggests that this compound could directly impact mitochondrial function. Previous studies in fact have shown that berberine inhibits NADH dehydrogenase and respiratory activity [23, 37] . In addition, mitochondrial participation in berberine-induced apoptosis has been demonstrated in a number of studies [2, 6, 11, 38] . Mitochondrially-relevant eVects of berberine exposure include changes in Bcl-2/Bax ratios, reactive oxygen species production, and a reduction in mitochondrial membrane potential [6, 11] . In this report, we demonstrate that berberine induces mitochondrial fragmentation and diminishes polarization in K1735-M2 and WM793 melanoma cells. We have extended these studies A number of studies have reported various eVects of berberine on cell cycle progression in diVerent types of cancer cell lines. G1 arrest has been reported for epidermal [12] and prostate [2] carcinoma cells. However, berberine can arrest gastric carcinoma [11] and HL-60 leukemia cells in G2/M [39] . In contrast, berberine has been reported to have little eVect on cell cycle traverse in U937 leukemia and B16 melanoma cell lines [40] . Our results with K1735-M2 melanoma cells show that the exact nature of cell cycle perturbation depends on the concentration of berberine used, with lower concentrations resulting in G1 arrest, and higher concentrations leading to a G2 arrest. Consequently, the conXicting information in the literature may reXect in part the diVerent concentrations of berberine used in diVerent studies. In addition, diVerent cells lines exhibit signiWcantly diVerent sensitivities to this alkaloid. For example, almost two orders of magnitude diVerence in IC 50 values were reported in the same study for leukemia and melanoma cell lines [40] .
Expression of key cell cycle regulatory molecules appears to be altered in response to berberine exposure. Down regulation of cyclins D1, D2 and E, and CDKs 2, 4 and 6, together with increased expression of the CKIs p21 and p27 were suggested to be responsible for the G1 arrest observed in berberine-treated prostate carcinoma cells [2] . In the studies showing G2/M arrest in promyelocytic leukemia and gastric carcinoma cells, it was found that the expression of cyclin B and CDK1 were decreased, while the levels of Wee1 were increased. The authors concluded that the G2/M arrest was caused by these eVects of berberine on these molecules [39] .
Early studies showed that low glucose levels can lead to a G1 arrest [41] , as can interfering with mitochondrial function [42] . A mechanistic link between ATP depletion and cell cycle arrest has recently been obtained by the demonstration that glucose limitation can activate the energy sensor AMPK, as well as p53 [43] . In Drosophila embryos, a 60% reduction in ATP levels resulting from a mutation in a mitochondrial electron transport chain protein allows cells to survive, grow, and diVerentiate, but blocks cell division via activation of AMPK. AMPK activation activates p53, reduces levels of cyclin E, and results in a G1 arrest [44] . In addition, reducing ATP levels with mitochondrial poisons also may result in a down-regulation of D-type cyclins, further contributing to a G1 arrest [45] . We propose that the increase in the percentage of M2 cells in G1 following lower doses (25 and 50 M) of berberine reXect the eVects of mitochondrially-concentrated berberine on respiratory function, resulting in lower ATP levels and activation of a G1 ATP checkpoint. This proposal is supported by the Wnding that ATP levels are reduced in cells treated with berberine (Pereira et al. submitted).
Berberine has been reported to inhibit DNA synthesis [46] and induce S-phase cell cycle arrest [11] . We found Fig. 10 EpiXuorescence micrographs showing the eVects of berberine on mitochondrial morphology and membrane polarization in two diVerent melanoma cell lines. K1735-M2 mouse and WM793 human melanoma cells were treated with vehicle only (0.1% DMSO, control) or 25 M berberine for 6 h prior to labeling nuclei with Hoechst, and mitochondria with the polarization-dependent probe TMRM. Note that berberine treatment causes mitochondrial fragmentation and a reduction in polarization (Xuorescence intensity) in both melanoma cell lines. Other than these mitochondrial eVects, the cells look morphologically very similar to the controls that in M2 melanoma cells, short-term exposure to berberine had little direct eVect on DNA synthesis except at very high doses. The ability of high concentrations (100 M) of berberine to arrest DNA synthesis was maintained for extended periods of time, namely, up to 4 days of treatment, the longest time point examined in this study. Because berberine is a DNA-binding compound, we presume that the rapid inhibition of DNA synthesis by high concentrations of berberine reXects altered replication across berberine-bound DNA, or inhibition of the replication complex itself. In contrast, lower concentrations of berberine (25 and 50 M) do not immediately block DNA synthesis, but instead exhibit a delayed eVect on BrdU uptake. BrdU-labeled cells could be found at all time points in cultures treated with 25 M berberine, but the number of labeled cells appeared to be diminished with extended drug exposure times (24 h and longer). Notably, BrdU uptake could be completely suppressed in cultures incubated in 50 M berberine, but this eVect took between 48 and 96 h to occur. These observations, together with the Xow cytometry data, suggest that lower doses of berberine (<100 M) allow cells to progress through S-phase, but subsequent entry into S is inhibited due to cell cycle arrest. At low concentrations of berberine, this arrest may reXect mitochondrial perturbation and initiation of the G1 "ATP checkpoint" described above. Higher concentrations of berberine resulted in a G2/M arrest, which is suggestive of a DNA damage/p53 activation response [47, 48] . Although we did not directly assay DNA damage in this study, previous workers have presented evidence for berberine-induced DNA damage and p53 activation [11, 38, 46] .
Our results demonstrate that diVerent concentrations of berberine lead to distinct cellular responses that are correlated with speciWc cellular localization patterns. Interestingly, an earlier study also correlated diVerences in berberine concentration and distribution with the responses of Balb/c 3T3 cells. In that study, 100 M berberine was mostly located in the cytoplasm and induced a G2/M arrest (similar to our results), while 200 M was concentrated in the nucleus and triggered apoptosis [25] . Together, these data suggest that the following multiphase model of action can be proposed: low concentrations of berberine are selectively accumulated by mitochondria, resulting in altered mitochondrial function, a reduction in ATP synthesis, activation of a G1 energy checkpoint, and consequently a slowing or arrest of cell proliferation. Higher concentrations of berberine saturate the mitochondrial binding capacity and subsequently accumulate in the cytoplasm and nucleus, and directly interfere with DNA synthesis. The nuclear eVects of high concentrations of berberine may activate p53 and Wee1, and inhibit cyclin B, leading to a G2 block prior to entry into M-phase. Very high concentrations may result in cell cycle perturbation and/or DNA damage suYcient to trigger apoptosis. It therefore appears that berberine would function more as a mitochondriotropic and cytostatic agent than a nuclear-damaging and cytotoxic agent at clinically relevant concentrations. It is possible that these multiphase eVects resulting from dose-dependent patterns of intracellular berberine localization can be exploited in the future to treat cell proliferative diseases where arrest of cell growth instead of induction of cell death is an acceptable treatment outcome, as well as in the ongoing search for natural products that synergize with current standard-of-care chemotherapeutics.
